Nyxoah Announces Partnership with ResMed in Germany

Nyxoah Announces Partnership with ResMed in Germany

Nyxoah Announces Partnership with ResMed in Germany

Creates a continuum of care in the German obstructive

Mont-Saint-Guibert, Belgium -

September 28, 2023, 10:30pm CET / 4:30pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"),

a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea

(OSA), today announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration

in the German market.

Nyxoah and ResMed Germany will establish

a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. Together, the companies

will work to accelerate patient identification and better support patient set-up on the appropriate therapy. The companies will collaborate

OSA helplines and direct-to-consumer marketing initiatives

Sales and marketing efforts targeting ENTs and sleep physicians

Patient and clinician educational programs and symposiums

"We are thrilled to partner with

ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life

and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and

Nyxoah will heighten awareness of OSA and increase therapy penetration," commented Olivier Taelman, Nyxoah's Chief Executive

Officer. "The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether

that is a mandibular device, continuous positive airway pressure (CPAP), or hypoglossal nerve stimulation (HGNS)."

"It is our joint goal to enable more

patients to receive effective, personalized therapy," said Katrin Pucknat, President, ResMed Germany. "Over 95 percent of

patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their

therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around

therapy options and empower patients to benefit from improved health outcomes."

Nyxoah is a medical technology company focused on the development

and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system,

a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered

breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision

that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of

the BLAST OSA study, the Genio system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP

study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients,

currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study

for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution - CE marked since 2019. Investigational device

in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in

this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements'

current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential

advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of

the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the

Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature,

forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results

or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties,

assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein.

Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the

"Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022, filed

with the Securities and Exchange Commission ("SEC") on March 22, 2023, and subsequent reports that the Company files

with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual

events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in

this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a

representation that such trends or activities will continue in the future. In addition, even if actual results or developments are

consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative

of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such

forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or

revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events,

conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do

so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such

person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor

does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or

the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak

only as of the date of this press release.

David DeMartino, Chief Strategy Officer

ENGLISH_Nyxoah - RMD Parternship